


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C07D 405/06, A61K 31/505, C07D 311/64, 239/49</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 97/20839</b> (43) International Publication Date: 12 June 1997 (12.06.97)</p>
<p>(21) International Application Number: PCT/EP96/05151 (22) International Filing Date: 22 November 1996 (22.11.96) (30) Priority Data: 3425/95 4 December 1995 (04.12.95) CH (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH). (72) Inventor: MASCIADRI, Raffaello; Klybeckstrasse 228, CH-4057 Basle (CH). (74) Agent: MAHE, Jean; Grenzacherstrasse 124, CH-4070 Basle (CH).</p>		<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL</p> <p>(57) Abstract</p> <p>Diaminopyrimidines of general formula (I) wherein either R<sup>1</sup> signifies straight-chain C<sub>5-10</sub>-alkyl, branched C<sub>3-5</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl or C<sub>3-5</sub>-ω-carboxyalkyl and R<sup>2</sup> and R<sup>3</sup> signify C<sub>1-5</sub>-alkyl; or R<sup>1</sup> signifies hydrogen, R<sup>2</sup> signifies C<sub>3-5</sub>-ω-carboxyalkyl and R<sup>3</sup> signifies C<sub>1-5</sub>-alkyl; and their pharmaceutically acceptable acid addition salts have antibiotic properties and can be used in the control or prevention of infectious diseases.</p> <div style="text-align: center;">  <p>(I)</p> </div>		

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

# DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL

The present invention is concerned with compounds of general formula I



wherein

10 either

R<sup>1</sup> signifies straight-chain C<sub>5-10</sub>-alkyl, branched C<sub>3-5</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl or C<sub>3-5</sub>-ω-carboxyalkyl and R<sup>2</sup> and R<sup>3</sup> signify C<sub>1-5</sub>-alkyl;

or

15 R<sup>1</sup> signifies hydrogen, R<sup>2</sup> signifies C<sub>3-5</sub>-ω-carboxyalkyl and R<sup>3</sup> signifies C<sub>1-5</sub>-alkyl;

and their pharmaceutically acceptable acid addition salts.

20 These compounds are novel and have valuable antibiotic properties. They can be used in the control or prevention of infectious diseases. In particular, they exhibit a pronounced antibacterial activity, even against multiresistant, gram-positive strains and against opportunistic pathogens such as e.g. *Pneumocystis carinii*. The compounds can also be administered in  
25 combination with known antibacterially active substances and then exhibit synergistic effects. Typical combination partners are e.g. sulphonamides which can be admixed in different proportions with the compounds of formula I or their salts.

30 Objects of the present invention are compounds of formula I, their readily hydrolyzable esters and pharmaceutically acceptable salts per se and for use as therapeutically active substances; medicaments based on these substances, optionally in combination with sulphonamides, and their production; the use of

these substances as medicaments and for the production of antibacterially active medicaments; as well as the manufacture of the compounds of formula I and their pharmaceutically acceptable salts and intermediates for their manufacture.

5

The terms C<sub>1-5</sub>, C<sub>3-5</sub> and C<sub>5-10</sub> denote the number of carbon atoms in the groups in question. Examples of C<sub>1-5</sub>-alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl and isomers thereof and n-pentyl and isomers thereof. Cyclopropyl, cyclobutyl, cyclo-  
10 pentyl and cyclohexyl are examples of C<sub>3-6</sub>-cycloalkyl groups. n-Pentyl, n-hexyl and n-heptyl are examples of straight-chain C<sub>5-10</sub>-alkyl groups. Isopropyl, sec.butyl and amyl are examples of branched C<sub>3-5</sub>-alkyl groups. ω-Carboxypropyl is a preferred C<sub>3-5</sub>-ω-carboxyalkyl group.


15

A preferred group of compounds of formula I comprises those in which R<sup>1</sup> signifies straight-chain C<sub>5-10</sub>-alkyl, branched C<sub>3-5</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl or C<sub>3-5</sub>-ω-carboxyalkyl.

20

The compounds of formula I can be manufactured in accordance with the invention by

a) cyclizing a compound of the formula




25

in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above significance;

or

30

b) reacting a compound of the formula



III

in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above significance and X represents a leaving group,

5 with guanidine and cleaving off protecting groups present,

and, if desired, converting a thus-obtained compound of formula I into a pharmaceutically usable salt.

10 The cyclization in accordance with process variant a) can be carried out in a manner known per se, e.g. by heating a compound of formula II, conveniently in a high-boiling solvent such as N,N-diethylaniline, polyethylene glycol 400, nitrobenzene, o-dichlorobenzene or diphenyl ether, e.g. to about 180-220°C; or by  
15 treating it with a silver or mercury salt in a chlorinated solvent at about 20-120°C, see in this respect W.K.Anderson and E.J.LaVoie, J. Org. Chem., 38, 3832 (1973), Chem. Reviews 84, 221-223 (1984) and S.M.Daluge, P.M.Skonezny, EP 0051879 (11.11.1981).

20


The reaction in accordance with process variant b) can also be effected in a manner known per se (see e.g. P.S. Manchand et al., J.Org. Chem. 57, 3531-3535 (1992)). Alkoxy such as methoxy, arylamino such as anilino and morpholino are examples of leaving  
25 groups X.

The compounds of formula I which form pharmaceutically acceptable acid addition salts with organic and inorganic acids. Examples of acid addition salts of compounds of formula I are  
30 salts with mineral acids, for example hydrohalic acids such as hydrochloric acid, hydrogen bromide and hydrogen iodide, sulphuric acid, nitric acid, phosphoric acid and the like, salts with organic sulphonic acids, for example with alkyl- and

arylsulphonic acids such as methanesulphonic acid, p-toluene-sulphonic acid, benzenesulphonic acid and the like, as well as salts with organic carboxylic acids, for example with acetic acid, tartaric acid, maleic acid, citric acid, benzoic acid, salicylic  
5 acid, ascorbic acid and the like.

The compounds of formula I which contain a carboxyl group also form pharmaceutically acceptable salts with bases. Examples of such salts of compounds of formula I are alkali metal  
10 salts, for example sodium and potassium salts, ammonium salts, salts with organic bases, for example with amines such as diisopropylamine, benzylamine, dibenzylamine, triethanolamine, triethylamine, N,N-dibenzylethylenediamine, N-methylmorpholine, pyridine, piperazine, N-ethylpiperidine, N-methyl-D-glucamine  
15 and procaine, or with amino acids such as arginine and lysine.

The compounds of formulae II and III are novel and are also objects of the invention. They can be prepared according to the following Reaction Schemes in which  $R^1$ ,  $R^2$ ,  $R^3$  and X have the  
20 above significance.

Reaction Scheme 1

## 5 Reaction A1

- This reaction can be carried out according to methods known per se (see e.g. O. Mitsunobu, Synthesis 1981, 1). It is preferably carried out in an inert solvent such as e.g. dichloromethane, tetrahydrofuran or toluene in a temperature range of -10°C to +50°C in the presence of triphenylphosphine and a dialkyl azodicarboxylate. Where the propargyl halide or tosylate corresponding to the alcohol (2) is accessible, a normal alkylation of the phenol group can also be carried out (see reaction D3).


## 15 Reaction B1

This reaction can also be carried out according to methods known per se in analogy to process variant a) described above for the manufacture of compounds of formula I.

## Reaction C1

This reaction can also be carried out according to methods known per se. It is preferably carried out in an inert solvent such as e.g. dimethyl sulphoxide, N,N-dimethylformamide, etc. in a temperature range of 20°C to 100°C in the presence of a strong base such as potassium tert.-butylate or sodium hydride, see e.g. P.S. Manchand et al., J. Org. Chem. 57, 3531-3535 (1992).

## Reaction Scheme 2



## Reaction A2

This reaction can also be carried out according to methods known per se (see D.R.M. Walton and F.Waugh, J. Organomet. Chem. 37, 45 (1972) and K.C.Nicolaou et al, J. Am. Chem. Soc., 106, 3548 (1984)). It is preferably carried out in an inert solvent such as e.g. dichloromethane in a temperature range of -30°C to 0°C in the presence of stoichiometric amounts of aluminium chloride and bis(trimethylsilyl)-acetylene.



## Reaction B2

This reaction can also be carried out according to methods known per se (see A.L.Gemal and J.-L.Luche, J. Am. Chem. Soc., 103, 5454 (1981)).

5


## Reaction C2

This reaction can also be carried out according to methods known per se.

## 10 Reaction D2

This reaction can also be carried out according to methods known per se, see J.A.Katzenellenbogen et al, J. Org. Chem. 54, 2624 (1991) (for R<sup>4</sup> = tetramethylsilyl) and K.Mori et al., Liebigs Ann. 1991, 529.

15

Reaction Scheme 3

## Reaction A3

This reaction is carried out analogously to reaction A1.

5

The starting material (8) is known, see L. Jurd, J. Am. Chem. Soc., 81, 4606 (1959).

## Reaction B3

10 This reaction can also be carried out according to methods known per se. Preferably, compound (9) in an inert solvent such as e.g. dichloromethane, tetrahydrofuran or toluene is treated with a protic acid such as hydrochloric acid, sulphuric acid or trifluoroacetic acid in the presence of water in a temperature  
15 range of 20°C to 100°C.

## Reaction C3

A selective alkylation of the 4-hydroxy group in compound (11) can be accomplished by reaction with an alkyl iodide in the  
20 presence of a weak base such as sodium hydrogen carbonate at 0°C to 30°C in an aprotic dipolar solvent such as N,N-dimethyl-formamide.

## Reaction D3

25 This reaction can also be carried out according to methods known per se. It can be carried out using an alkyl halide either in an inert solvent such as e.g. dimethyl sulphoxide, N,N-dimethyl-formamide, etc. in a temperature range of 10°C to 50°C in the presence of a strong base such as potassium tert.-butylate or  
30 sodium hydride, or in a polar solvent such as acetone, 2-butanone etc. in a temperature range of 50°C to 100°C in the presence of potassium carbonate.

## Reaction E3

35 This reaction can also be carried out according to methods known per se analogously to variant a) of the process referred to a) above.


## Reaction F3

This reaction can be carried out in one step or in two steps according to methods known per se. The one-step method (see R.Kanazawa and T.Tokoroyama, Synthesis 1976, 526) is preferably carried out at -30° to -10°C. The two-step method involves a complete reduction to the corresponding alcohol with aluminium hydrides such as DIBALH or REDAL and subsequent re-oxidation to the aldehyde with activated manganese dioxide or by Swern oxidation with dimethyl sulphoxide/oxalyl chloride.

## Reaction G3


This reaction corresponds to reaction C1.

Compounds of formula II can be prepared from compounds of the formula



and compounds of formula (2) analogously to reaction A1.

Compounds of formula II can be prepared from compounds of formulae (2) and (14)



in analogy to reaction A1.

The preparation of compounds II and III is, moreover, described in the Examples.

As already mentioned, the compounds of formula I and their pharmaceutically acceptable salts have valuable antibacterial properties. They are active against a large number of pathogenic microorganisms such as e.g. *Staphylococcus aureus*, *Pneumocystis carinii* etc. by virtue of their activity in inhibiting bacterial dihydrofolate reductase (DHFR).

The inhibition of this enzyme was taken as a measurement for the antibacterial activity. It is determined using the method of Baccanari and Joyner (Biochemistry 20, 1710 (1981); see also P.G. Hartman et al., FEB 242, 157-160 (1988).

The IC<sub>50</sub> values (concentration at which the enzyme is inhibited by 50%) are determined by means of a graph.

The following Table contains inhibitory concentrations obtained for representative members of the class of compound defined by formula I and determined in the above test. The IC<sub>50</sub> values (μM) against the purified DHFR of the reference strain *S. aureus* ATCC 25923 as well as against the purified DHFR of the multiresistant strain *S. aureus* 157/4696 are given. The third column shows the IC<sub>50</sub> values (μM) against the purified DHFR of the opportunistic pathogen *P. carinii*. The inhibition constants of trimethoprim (TMP) are also given as a comparison.

Compound of Example No.	<i>S. aureus</i> ATCC 25923	<i>S. aureus</i> 157/4696	<i>P. carinii</i>
6	0.005	0.770	0.220
7	0.016	0.850	2.800
8	0.001	1.000	1.000
9	0.001	0.900	3.000
10	0.005	0.520	0.040
TMP	0.007	2.250	5.500

The products in accordance with the invention can be used as medicaments, e.g. in the form of pharmaceutical preparations

for enteral or parenteral administration. For example, the products in accordance with the invention can be administered perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, 5 rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled 10 in the art by bringing the substances in accordance with the invention, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, the 15 usual pharmaceutical adjuvants.

Both inorganic and organic carrier materials are suitable as such carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as 20 carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine 25 capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and glucose. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, 30 for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.

The usual preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for 35 varying the osmotic pressure, buffers, masking agents and anti-oxidants come into consideration as pharmaceutical adjuvants.

For parenteral administration the compounds of formula I and, respectively, their salts are preferably provided as lyophilizates or dry powders for dilution with usual carriers such as water or isotonic saline.

5

The compounds of formula I are distinguished by a high antibacterial activity and, respectively, a pronounced synergistic effect in combination with sulphonamides and good tolerance. They inhibit bacterial dihydrofolate reductase and potentiate the  
10 antibacterial activity of sulphonamides such as e.g. sulfisoxazole, sulfadimethoxine, sulfamethoxazole, 4-sulphanilamido-5,6-dimethoxy-pyrimidine, 2-sulphanilamido-4,5-dimethyl-pyrimidine or sulfaquinoxaline, sulfadiazine, sulfamonomethoxine, 2-sulphanilamido-4,5-dimethyl-isoxazole and other  
15 inhibitors of enzymes which are involved in folic acid biosynthesis, such as e.g. pteridine derivatives.

Oral, rectal and parenteral administration come into consideration in human medicine for such combinations of one or  
20 more compounds I in accordance with the invention with sulphonamides. The ratio of compound I to sulphonamide can vary within a wide range; it amounts to e.g. between 1:40 (parts by weight) and 1:1 (parts by weight); preferred ratios are 1:10 to 1:2.

25 Thus, e.g., a tablet can contain 80 mg of a compound I in accordance with the invention and 400 mg of sulfamethoxazole, a tablet for children can contain 20 mg of a compound I in accordance with the invention and 100 mg of sulfamethoxazole; syrup (per 5 ml) can contain 40 mg of compound I and 200 mg of  
30 sulfamethoxazole.

A daily dosage of about 0.2 g to about 2 g of a compound of formula I in accordance with the invention comes into consideration for adults.

35

The following Examples illustrate the invention in more detail. Examples 1-4 describe the preparation of starting materials of formulae II and III, while Examples 5-10 describe

the manufacture of the compounds of formula I. The temperatures are given in degrees Celsius.

### Example 1

5

Preparation of compounds (2):

a) 29.3 g of aluminium(III) chloride were suspended in 300 ml of dichloromethane under argon and cooled to -30°C. A solution of  
10 44.2 ml of bis(trimethylsilyl)acetylene and 18.3 ml of cyclopropanecarboxylic acid chloride were added at -30°C over 15 min. The reaction mixture was left to warm to -10°C, poured into a vigorously stirred mixture of 250 ml of 3N HCl and 500 g of ice, stirred for a further 10 min. and finally extracted with  
15 2 x 750 ml of hexane. The organic phases were washed in succession with in each case 750 ml of saturated NaCl, NaHCO<sub>3</sub> and NaCl. The organic phases were dried and evaporated. Distillation of the crude product at 95°C/14 mbar yielded  
20 1-cyclopropyl-3-trimethylsilylprop-2-yn-1-one as a colourless oil.

b) 37.3 g of Cer(III) chloride heptahydrate were added to a solution of 16.6 g of (RS)-1-cyclopropyl-3-trimethylsilylprop-2-yn-1-one in 170 ml of methanol and the mixture was  
25 stirred at 20°C until all had dissolved. Then, 1.9 g of sodium borohydride were added cautiously in portions in order to avoid excessive foaming. The resulting white suspension was cooled to 10°C, treated with 50 ml of 1N HCl and then diluted with 150 ml of ice-water. This mixture was extracted with 2 x 400 ml of  
30 hexane. The hexane phases were washed with 300 ml of ice-water, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. Distillation of the crude product at 106°C/14 mbar gave (RS)-1-cyclopropyl-3-trimethylsilylprop-2-yn-1-ol as a yellowish oil.

35 c) 7.8 g of (RS)-1-cyclopropyl-3-trimethylsilylprop-2-yn-1-ol were dissolved in 80 ml of methanol, treated with 0.64 g of potassium carbonate and stirred at 20°C for 3 hrs. Then, the methanol was removed on a rotary evaporator at 200 mbar/40°C.

The residue was taken up in 80 ml of diethyl ether and extracted with 80 ml of ice-water. The crude product was distilled at 14 mbar/60°C (danger of explosion!). (RS)-1-Cyclopropyl-prop-2-yn-1-ol was obtained as a colourless oil.

5

d) In analogy to Example 1a), from glutaric acid monomethyl-ester chloride there was obtained methyl 5-oxo-7-trimethyl-silanyl-hept-6-ynoate.

10 e) In analogy to Example 1b), from methyl 5-oxo-7-trimethyl-silanyl-hept-6-ynoate there was obtained methyl (RS)-5-hydroxy-7-trimethylsilanyl-hept-6-ynoate.

15 f) In analogy to Example 1c), from methyl (RS)-5-hydroxy-7-trimethylsilanyl-hept-6-ynoate there was obtained methyl (RS)-5-hydroxy-hept-6-ynoate.

### Example 2

20 Preparation of compounds (3):

a) 7.3 g of 3,4-dimethoxy-5-hydroxybenzaldehyde, 6.9 g of (RS)-1-cyclopropyl-3-trimethylsilanyl-prop-2-yn-1-ol and 10.5 g of triphenylphosphine were dissolved in 60 ml of toluene  
25 under argon and cooled to 5°C. A solution of 6.9 ml of diethyl azodicarboxylate in 20 ml of toluene was slowly added dropwise thereto at 5°C over 50 min. The resulting reaction mixture was chromatographed directly on silica gel in toluene. There were obtained 4.2 g of a yellow oil (HPLC 80%). This was dissolved in  
30 40 ml of methanol and stirred at 20°C with 553 mg of potassium carbonate for 3 hrs. Extraction was effected with in each case 2 x 50 ml of ethyl acetate and water. For crystallization, it was dissolved in 10 ml of hot ethyl acetate and then diluted with 20 ml of hexane. There was obtained (RS)-3-(1-cyclopropyl-prop-2-ynyloxy)-4,5-dimethoxy-benzaldehyde as white crystals.  
35

b) 63.6 g of methyl 3,4-dimethoxy-5-hydroxy-benzoate [E.Späth and H.Röder, Monatsh. für Chemie, 43, 93 (1923)], 38.5 g



- of (RS)-1-cyclopropyl-prop-2-yn-1-ol and 118 g of triphenylphosphine were dissolved in 600 ml of toluene under argon and cooled to 5°C. A solution of 70 ml of diethyl azodicarboxylate in 150 ml of toluene was slowly added dropwise thereto at 5°C over  
5 90 min. The mixture was stirred at 5°C for a further 1 hr. and at 20°C for 3 hrs. Then, 300 ml of toluene were distilled off on a rotary evaporator and the suspension obtained was stirred in an ice bath for 30 min. The separated triphenylphosphine oxide was filtered off and the filtrate was evaporated. The resulting oil  
10 was chromatographed on silica gel with hexane/ethyl acetate 4:1, then 3:1. Crystallization was effected from diethyl ether and hexane. There was obtained methyl (RS)-3-(1-cyclopropyl-prop-2-ynyloxy)-4,5-dimethoxy-benzoate as white crystals.
- 15 c) In analogy to Example 2a), from methyl (RS)-5-hydroxy-7-trimethylsilyl-hept-6-ynoate there was obtained methyl (RS)-5-(5-formyl-2,3-dimethoxy-phenoxy)-hept-6-ynoate.
- d) In analogy to Example 2a), from (RS)-1-octyn-3-ol there  
20 was obtained (RS)-3,4-dimethoxy-5-(1-pentyl-prop-2-ynyloxy)-benzaldehyde.
- e) In analogy to Example 2a), from (RS)-4-methyl-1-pentyn-3-ol there was obtained (RS)-3-(1-isopropyl-prop-2-ynyloxy)-4,5-  
25 dimethoxy-benzaldehyde.
- f) In analogy to Example 2a), from (RS)-5-methyl-1-hexyn-3-ol there was obtained (RS)-3-(1-isobutyl-prop-2-ynyloxy)-4,5-dimethoxy-benzaldehyde.

30

### Example 3

Preparation of compounds (4):

- 35 a) 33.5 g of methyl (RS)-3-(1-cyclopropyl-prop-2-ynyloxy)-4,5-dimethoxy-benzoate were dissolved in 330 ml of N,N-diethylaniline, heated to 200°C under argon and stirred at 200°C for a further 5 hrs. The solvent was distilled off at 90°C/1 mbar and

the residue was extracted: 2 x 1.5 l of diethyl ether, 2 x 1.5 l of 1N HCl, 2 x 1.5 l of saturated NaCl. The oil obtained was purified by silica gel chromatography with toluene, then toluene/ethyl acetate 9:1. Crystallization was effected from diethyl ether and  
5 hexane. Methyl (RS)-2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-carboxylate was obtained as white crystals.

b1) 2.4 g of (RS)-3-(1-cyclopropyl-prop-2-ynyloxy)-4,5-dimethoxy-benzaldehyde were dissolved in 20 ml of N,N-diethyl-  
10 aniline, heated to 200°C under argon and stirred at 200°C for a further 1 hr. The solvent was distilled off at 90°C/1 mbar and the residue was extracted: 2 x 100 ml of diethyl ether, 2 x 100 ml of 1N HCl, 2 x 100 ml of saturated NaCl. The crude product was purified by two-fold silica gel chromatography with  
15 dichloromethane and, respectively, ethyl acetate/hexane 5:1. (RS)-2-Cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-carbaldehyde was obtained as a brown oil (HPLC 96%).

b2) A solution of 48 ml of morpholine in 50 ml of toluene was  
20 added dropwise over 1 hr. under argon to an ice-cold solution of 143 ml of sodium dihydrido-bis-(2-methoxyethoxy) aluminate (3.5M in toluene) diluted with 200 ml of toluene. The resulting reduction solution was then added dropwise under argon during 1 hr. to a solution, cooled to -35°C, of 46 g of methyl (RS)-2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-carboxylate in  
25 200 ml of toluene and the mixture was stirred at -15°C for a further 4 hrs. The reaction was stopped by the cautious addition of 40 ml of 3N NaOH and the mixture was left to warm. Extraction: 3 x 600 ml of ice-water, 1 x 600 ml of toluene.  
30 Chromatography: silica gel, hexane/ethyl acetate 5:1. Crystallization from diethyl ether/ hexane. (RS)-2-Cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-carbaldehyde was obtained as a solid.

35 c) In analogy to Example 3a), from methyl (RS)-5-(5-formyl-2,3-dimethoxy-phenoxy)-hept-6-ynoate there was obtained methyl (RS)-4-(5-formyl-7,8-dimethoxy-2H-1-benzopyran-2-yl)-butyrate.

- d) 1.5 g of methyl (RS)-4-(5-formyl-7,8-dimethoxy-2H-1-benzopyran-2-yl)-butyrate were dissolved in 10 ml of tetrahydrofuran under argon and then treated with 1 ml of 1N NaOH and stirred at 20°C for 1.5 hrs. The reaction mixture was acidified with 9 ml of 1N HCl, saturated with NaCl and extracted with 2 x 20 ml of ethyl acetate. The crude product was chromatographed on silica gel in ethyl acetate and chromatographed from toluene/hexane 1:1. There was obtained (RS)-4-(5-formyl-7,8-dimethoxy-2H-1-benzopyran-2-yl)-butyric acid as white crystals.
- e) In analogy to Example 3a), from (RS)-3,4-dimethoxy-5-(1-pentyl-prop-2-ynyloxy)-benzaldehyde there was obtained (RS)-7,8-dimethoxy-2-pentyl-2H-1-benzopyran-5-carbaldehyde.
- f) In analogy to Example 3a), from (RS)-3-(1-isopropyl-prop-2-ynyloxy)-4,5-dimethoxy-benzaldehyde there was obtained (RS)-2-isopropyl-7,8-dimethoxy-2H-1-benzopyran-5-carbaldehyde.
- g) In analogy to Example 3a), from (RS)-3-(1-isobutyl-prop-2-ynyloxy)-4,5-dimethoxy-benzaldehyde there was obtained (RS)-2-isobutyl-7,8-dimethoxy-2H-1-benzopyran-5-carbaldehyde.

#### Example 4

Preparation of compounds of formula III:

- 30 g of (RS)-2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-carbaldehyde and 17.5 g of 3-anilinopropionitrile were dissolved in 300 ml of dimethyl sulphoxide under argon, cooled to 10°C and treated portionwise with 13.5 g of potassium tert.-butylate. Subsequently, the mixture was stirred at 10°C for a further 1 hr. and at 20°C for 5 hrs. For the working up, the mixture was poured on to 3 l of ice/water and extracted: 2 x 3 l of ethyl acetate, 2 x 3 l of water. The crude product was purified by silica gel chromatography with hexane/ethyl acetate 5:1 to 2:1 and crystallized from hexane/ethyl acetate. (RS)-3-

Anilino-2-(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl-methyl)acrylonitrile was obtained as white crystals, m.p. 140°C.

#### Example 5

5

1.45 g of guanidine hydrochloride were dissolved in 20 ml of ethanol, stirred with 1.7 g of potassium tert.butylate for 15 min. and then filtered through Dicalite. The filtrate was added to 2 g of (RS)-3-anilino-2-(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl-methyl)acrylonitrile and the mixture was boiled at reflux for 8 hrs. The product crystallized out spontaneously upon cooling. Recrystallization from 90 ml of ethanol gave (RS)-5-(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl-methyl)-pyrimidine-2,4-diamine as white crystals, m.p. 229°C.

#### Example 6

In analogy to Examples 4 and 5, from (RS)-4-(5-formyl-7,8-dimethoxy-2H-1-benzopyran-2-yl)-butyric acid there was obtained (RS)-4-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-7,8-dimethoxy-2H-1-benzopyran-2-yl]-butyric acid, m.p. 124°C.

#### Example 7

25

In analogy to Examples 4 and 5, from (RS)-7,8-dimethoxy-2-pentyl-2H-1-benzopyran-5-carbaldehyde there was obtained (RS)-5-(7,8-dimethoxy-2-pentyl-2H-1-benzopyran-5-ylmethyl)-pyrimidine-2,4-diamine, m.p. 188°C.

30

#### Example 8

In analogy to Examples 4 and 5, from 2-isopropyl-7,8-dimethoxy-2H-1-benzopyran-5-carbaldehyde there was obtained (RS)-5-(2-isopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl-methyl)-pyrimidine-2,4-diamine, m.p. 223°C.

35

Example 9

In analogy to Examples 4 and 5, from (RS)-2-isobutyl-7,8-dimethoxy-2H-1-benzopyran-5-carbaldehyde there was obtained  
 5 (RS)-5-(2-isobutyl-7,8-dimethoxy-2H-1-benzopyran-5-yl-methyl)-pyrimidine-2,4-diamine, m.p. 214°C.

Example 10

10 In analogy to Examples 4 and 5, from tert-butyl 4-(5-formyl-8-methoxy-2H-1-benzopyran-7-yloxy)-butyrate via tert-butyl 4-[5-(2-cyano-3-phenylamino-allyl)-8-methoxy-2H-chromen-7-yloxy]-butyrate there was obtained 4-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-8-methoxy-2H-1-benzopyran-7-yloxy]-butyric acid, m.p. 250°C.  
 15

Example ATablets


20	Sulfamethoxazole	400 mg
	Compound of formula I, e.g. 4-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-8-methoxy-2H-1-benzopyran-7-yloxy]-butyric acid	80 mg
25	PRIMOJEL (starch derivative)	6 mg
	POVIDONE K30 (polyvinylpyrrolidone)	8 mg
	Magnesium stearate	<u>6 mg</u>
	Total weight	500 mg

30 Example B

	Compound of formula I, e.g. 4-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-8-methoxy-2H-1-benzopyran-7-yloxy]-butyric acid	100 mg
35	Corn starch	15 mg
	Talc	3 mg
	Magnesium stearate	<u>2 mg</u>
		120 mg

Claims

1. Compounds of general formula I



5

wherein

either

R<sup>1</sup> signifies straight-chain C<sub>5-10</sub>-alkyl, branched C<sub>3-5</sub>-alkyl,  
 10 C<sub>3-6</sub>-cycloalkyl or C<sub>3-5</sub>-ω-carboxyalkyl and R<sup>2</sup> and R<sup>3</sup> signify  
 C<sub>1-5</sub>-alkyl;

or

R<sup>1</sup> signifies hydrogen, R<sup>2</sup> signifies C<sub>3-5</sub>-ω-carboxyalkyl and R<sup>3</sup>  
 signifies C<sub>1-5</sub>-alkyl;  
 15 and their pharmaceutically acceptable acid addition salts.

2. Compounds according to claim 1, in which R<sup>1</sup> signifies  
 straight-chain C<sub>5-10</sub>-alkyl, branched C<sub>3-5</sub>-alkyl, C<sub>3-6</sub>-cyclo-  
 alkyl or C<sub>3-5</sub>-ω-carboxyalkyl.

20

3. The compounds

(RS)-5-(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-  
 yl-methyl)-pyrimidine-2,4-diamine,

25

(RS)-4-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-7,8-  
 dimethoxy-2H-1-benzopyran-2-yl]-butyric acid,

(RS)-5-(7,8-dimethoxy-2-pentyl-2H-1-benzopyran-5-yl-  
 30 methyl)-pyrimidine-2,4-diamine,


(RS)-5-(2-isopropyl-7,8-dimethoxy-2H-1-benzopyran-5-  
 ylmethyl)-pyrimidine-2,4-diamine and

21

4-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-8-methoxy-2H-1-benzopyran-7-yloxy]-butyric acid.

4. Compounds of the formula


5



wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the significance given in claim 1.

10

5. Compounds of the formula



15

in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the significance given in claim 1 and X represents a leaving group.


6. Compounds according to any one of claims 1-3 for use as medicaments.

20

7. A process for the manufacture of compounds of claims 1-3, which process comprises

a) cyclizing a compound of the formula

25




in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above significance;

or

5

b) reacting a compound of the formula



10 in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the above significance and X represents a leaving group,  
with guanidine and cleaving off protecting groups present,  
and, if desired, converting a thus-obtained compound of formula I  
15 into a pharmaceutically usable salt.

8. A medicament containing a compound according to any one of claims 1-3 and a therapeutically inert carrier.

20 9. The use of compounds according to any one of claims 1-3 as medicaments, especially in infectious diseases.

10. The use of compounds according to any one of claims 1-3 in the manufacture of antibioticly-active medicaments.

25

11. The invention as hereinbefore described.

\*\*\*



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/05151

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D405/06 A61K31/505 C07D311/64 C07D239/49

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 051 879 A (THE WELLCOME FOUNDATION LIMITED) 19 May 1982 * see examples, claims and pages 80-88 *	1-10
X	* see page 21, Formula (XVI) *	4
X	* see page 18, Formula (X) *	5
	-----	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

5 February 1997

Date of mailing of the international search report

24.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Lauro, P

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Appl. Application No

PCT/EP 96/05151

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-51879	19-05-82	AT-B- 384023	25-09-87
		AU-B- 549449	30-01-86
		AU-A- 7733481	20-05-82
		CA-A- 1186310	30-04-85
		CY-A- 1419	22-04-88
		EG-A- 16107	30-10-87
		GB-A,B 2087881	03-06-82
		HK-A- 23388	08-04-88
		JP-C- 1783158	31-08-93
		JP-B- 4074351	26-11-92
		JP-A- 57114581	16-07-82
		KE-A- 3650	01-08-86
		SU-A- 1424732	15-09-88
		SU-A- 1318148	15-06-87
		SU-A- 1306473	23-04-87
		SU-A- 1819264	30-05-93
		SU-A- 1535379	07-01-90
		US-A- 4438267	20-03-84
		US-A- 4587342	06-05-86
		US-A- 4603136	29-07-86
		US-A- 4761475	02-08-88